NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31
NewcelX Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026
$2.63+0.13 (+5.20%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 1.2
- Dividend yield
- –
Share price
−$13.87 (−84.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- 1.2
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.30M
- EPS, diluted
- $2.16
- Free cash flow
- -$2.77M
Nine years at a glance
Fiscal years 2017 to 2025, USD
Operating income
-$2.56M
Net income
-$8.30M
EPS, diluted
$2.16-11.1% YoY
Free cash flow
-$2.77M
Reported period